To date, full transcriptomic alterations induced by belinostat in solid tumor cells have solely been investigated in breast cancer cells, where treatment resulted in enrichment for pathways such as oxidative phosphorylation, cell cycle and ERBB signalling [36]. The gene discussed is EGFR; the disease is breast cancer.